Your browser is no longer supported. Please, upgrade your browser.
Cerus Corporation
Index- P/E- EPS (ttm)-0.40 Insider Own1.00% Shs Outstand166.57M Perf Week-1.43%
Market Cap1.22B Forward P/E- EPS next Y-0.32 Insider Trans-31.30% Shs Float163.66M Perf Month2.26%
Income-62.40M PEG- EPS next Q-0.09 Inst Own82.30% Short Float6.42% Perf Quarter11.37%
Sales107.10M P/S11.40 EPS this Y-16.50% Inst Trans0.14% Short Ratio5.47 Perf Half Y7.09%
Book/sh0.66 P/B10.98 EPS next Y13.50% ROA-30.80% Target Price9.30 Perf Year72.62%
Cash/sh0.80 P/C9.03 EPS next 5Y- ROE-63.50% 52W Range2.71 - 8.87 Perf YTD4.77%
Dividend- P/FCF- EPS past 5Y0.30% ROI-65.50% 52W High-18.26% Beta1.34
Dividend %- Quick Ratio3.40 Sales past 5Y20.80% Gross Margin64.30% 52W Low167.53% ATR0.48
Employees254 Current Ratio3.80 Sales Q/Q28.10% Oper. Margin-56.40% RSI (14)50.53 Volatility6.13% 6.72%
OptionableYes Debt/Eq0.41 EPS Q/Q33.40% Profit Margin-58.20% Rel Volume1.14 Prev Close7.55
ShortableYes LT Debt/Eq0.36 EarningsOct 29 AMC Payout- Avg Volume1.92M Price7.25
Recom1.40 SMA20-1.63% SMA506.09% SMA20014.11% Volume2,188,357 Change-3.97%
Oct-08-20Resumed BTIG Research Buy $9
Jun-16-20Resumed Cantor Fitzgerald Overweight $9
Feb-26-20Initiated BTIG Research Buy $7
Nov-13-19Upgrade BTIG Research Neutral → Buy $7
Aug-28-19Initiated Stifel Buy
Aug-23-19Resumed Stephens Overweight
Jan-05-18Resumed Cantor Fitzgerald Overweight
Dec-08-17Resumed BTIG Research Neutral
Jul-07-16Resumed Cantor Fitzgerald Buy $9
Dec-17-15Downgrade Wedbush Outperform → Neutral
May-02-14Reiterated MLV & Co Buy $8.50 → $6
Apr-24-13Reiterated Cantor Fitzgerald Buy $5.50 → $6
Mar-15-13Reiterated MLV & Co Buy $7.50 → $8.50
Apr-17-12Initiated Cantor Fitzgerald Buy $5.50
Feb-29-12Upgrade Robert W. Baird Neutral → Outperform $3 → $6
Nov-10-11Reiterated MLV & Co Buy $4 → $5
Jun-03-11Initiated Wedbush Outperform $4
Mar-04-11Downgrade Robert W. Baird Outperform → Neutral $4 → $3
Mar-09-10Upgrade Robert W. Baird Neutral → Outperform $3 → $5
Aug-26-09Upgrade Avondale Mkt Perform → Mkt Outperform $2 → $5
Jan-11-21 08:30AM  
Dec-15-20 08:30AM  
Dec-11-20 10:55PM  
Dec-07-20 12:11AM  
Dec-04-20 07:00PM  
Nov-30-20 12:00PM  
Nov-20-20 12:00PM  
Nov-12-20 08:30AM  
Nov-01-20 07:59AM  
Oct-30-20 03:30PM  
Oct-29-20 06:05PM  
Oct-28-20 10:13AM  
Oct-22-20 12:34PM  
Oct-19-20 08:30AM  
Oct-13-20 08:30AM  
Sep-28-20 08:30AM  
Sep-16-20 07:49AM  
Sep-09-20 08:30AM  
Aug-26-20 01:08PM  
Aug-25-20 08:38AM  
Aug-12-20 09:26AM  
Aug-11-20 06:48AM  
Aug-07-20 08:30AM  
Aug-05-20 02:01AM  
Aug-04-20 05:15PM  
Jul-30-20 08:30AM  
Jul-28-20 12:33PM  
Jul-23-20 08:30AM  
Jul-07-20 08:30AM  
Jul-06-20 10:01AM  
Jun-24-20 03:17PM  
Jun-17-20 11:30AM  
Jun-15-20 05:43PM  
Jun-12-20 08:30AM  
Jun-11-20 09:39AM  
May-27-20 12:00PM  
May-26-20 08:30AM  
May-07-20 12:15PM  
May-06-20 07:33AM  
May-05-20 06:45PM  
May-04-20 08:30AM  
Apr-29-20 10:05AM  
Apr-28-20 12:34PM  
Apr-24-20 08:30AM  
Apr-23-20 11:43AM  
Apr-20-20 05:50PM  
Apr-07-20 08:40AM  
Apr-06-20 08:30AM  
Apr-02-20 08:30AM  
Mar-26-20 08:30AM  
Mar-02-20 04:56PM  
Feb-25-20 03:25PM  
Feb-22-20 07:58AM  
Feb-20-20 04:01PM  
Feb-18-20 08:30AM  
Feb-12-20 08:30AM  
Feb-06-20 06:06AM  
Jan-31-20 04:01PM  
Jan-29-20 09:00AM  
Jan-28-20 04:01PM  
Jan-23-20 03:14PM  
Jan-21-20 08:30AM  
Jan-13-20 08:30AM  
Dec-30-19 02:08PM  
Dec-16-19 04:38PM  
Dec-12-19 08:30AM  
Nov-30-19 09:01AM  
Nov-13-19 08:30AM  
Nov-12-19 06:45AM  
Nov-08-19 08:30AM  
Nov-01-19 09:34AM  
Oct-30-19 06:45PM  
Oct-23-19 10:34AM  
Oct-21-19 08:30AM  
Oct-18-19 08:30AM  
Oct-13-19 09:36AM  
Sep-30-19 12:00PM  
Sep-27-19 08:30AM  
Sep-13-19 07:05AM  
Sep-03-19 06:02PM  
Aug-28-19 08:30AM  
Aug-14-19 09:44AM  
Aug-01-19 09:24PM  
Jul-25-19 10:34AM  
Jul-22-19 08:30AM  
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jayaraman Vivek KChief Operating OfficerDec 22Option Exercise4.3256,105242,400188,440Dec 28 05:44 PM
ANDERSON TIMOTHY BDirectorDec 22Option Exercise5.4030,000162,000240,101Dec 28 05:39 PM
Menard ChrystalChief Legal OfficerDec 22Option Exercise4.37211,327923,379134,001Dec 28 05:43 PM
ANDERSON TIMOTHY BDirectorDec 22Sale8.3139,336326,856200,765Dec 28 05:39 PM
Menard ChrystalChief Legal OfficerDec 22Sale8.00211,3271,690,61648,585Dec 28 05:43 PM
Jayaraman Vivek KChief Operating OfficerDec 22Sale8.0056,105448,840135,003Dec 28 05:44 PM
SCHULZE GAILDirectorDec 14Option Exercise2.4815,00037,20062,393Dec 15 08:51 PM
SCHULZE GAILDirectorDec 14Sale7.3262,393456,8170Dec 15 08:51 PM
Jayaraman Vivek KChief Commercial OfficerDec 11Option Exercise4.3318,89581,815178,898Dec 15 08:44 PM
Menard ChrystalChief Legal OfficerDec 11Option Exercise4.4341,363183,38370,460Dec 15 08:49 PM
Menard ChrystalChief Legal OfficerDec 11Sale8.0041,363330,90448,585Dec 15 08:49 PM
Jayaraman Vivek KChief Commercial OfficerDec 11Sale8.0043,895351,160135,003Dec 15 08:44 PM
Swisher Daniel N JRDirectorNov 17Option Exercise2.9010,00029,00069,868Nov 19 05:07 PM
Swisher Daniel N JRDirectorNov 17Sale6.2510,00062,50559,868Nov 19 05:07 PM
Green Kevin DennisChief Financial OfficerNov 10Sale5.4932,928180,86299,468Nov 12 06:57 PM
Greenman William MarinerPresident and CEOAug 26Option Exercise3.00100,000300,000925,849Aug 26 08:23 PM
ANDERSON TIMOTHY BDirectorAug 24Option Exercise4.8023,703113,774226,109Aug 26 08:18 PM
Benjamin Richard JChief Medical OfficerAug 24Option Exercise4.72100,000472,000141,763Aug 26 08:20 PM
Benjamin Richard JChief Medical OfficerAug 24Sale7.90100,000790,00041,763Aug 26 08:20 PM
ANDERSON TIMOTHY BDirectorAug 24Sale7.9016,008126,463210,101Aug 26 08:18 PM
Moore CarolSVP Reg. & QualityAug 12Option Exercise3.0030,00090,000141,751Aug 14 05:53 PM
Moore CarolSVP Reg. & QualityAug 12Sale6.8821,621148,752120,130Aug 14 05:53 PM
Green Kevin DennisChief Financial OfficerAug 10Option Exercise2.0880,000166,400200,981Aug 11 09:15 PM
Green Kevin DennisChief Financial OfficerAug 10Sale6.9668,585477,678132,396Aug 11 09:15 PM
ANDERSON TIMOTHY BDirectorAug 07Option Exercise4.3443,800190,092242,482Aug 11 09:16 PM
Menard ChrystalChief Legal OfficerAug 07Sale7.0723,621166,93048,585Aug 11 09:18 PM
ANDERSON TIMOTHY BDirectorAug 07Sale7.1240,076285,152202,406Aug 11 09:16 PM
Benjamin Richard JChief Medical OfficerJul 07Option Exercise4.58154,583708,028141,763Jul 09 08:45 PM
Benjamin Richard JChief Medical OfficerJul 07Sale7.20154,5831,113,04441,763Jul 09 08:45 PM
Moore CarolSVP Reg. & QualityJun 25Option Exercise2.08130,000270,400241,751Jun 26 08:06 PM
Moore CarolSVP Reg. & QualityJun 25Sale7.00130,000910,000111,751Jun 26 08:06 PM
Moore CarolSVP Reg. & QualityJun 01Option Exercise3.0030,02590,057141,751Jun 03 09:40 PM
Moore CarolSVP Reg. & QualityJun 01Sale6.5030,025195,163111,751Jun 03 09:40 PM
Menard ChrystalChief Legal OfficerMay 12Sale5.6720,351115,28872,206May 14 06:22 PM
CORASH LAURENCE MChief Scientific OfficerApr 22Option Exercise3.6694,800346,9681,897,558Apr 23 08:47 PM
Moore CarolSVP Reg. & QualityMar 17Sale3.5926,68495,92174,445Mar 24 09:29 PM
Menard ChrystalChief Legal OfficerMar 17Sale3.5926,53595,38555,285Mar 24 09:26 PM
Jayaraman Vivek KChief Commercial OfficerMar 17Sale3.5923,50084,475111,371Mar 24 09:24 PM
Greenman William MarinerPresident and CEOMar 17Sale3.59108,011388,267699,590Mar 24 09:19 PM
Green Kevin DennisChief Financial OfficerMar 17Sale3.5926,62595,70983,612Mar 24 09:15 PM
CORASH LAURENCE MChief Scientific OfficerMar 17Sale3.5917,50062,9071,802,758Mar 24 09:12 PM
Benjamin Richard JChief Medical OfficerMar 17Sale3.5926,57095,5114,478Mar 24 09:09 PM
MOORE TIMOTHY L.DirectorFeb 11Buy4.753,61417,1657,911Feb 13 05:54 PM
ANDERSON TIMOTHY BDirectorJan 29Buy4.159,63940,002187,498Feb 03 08:20 PM
MOORE TIMOTHY L.DirectorJan 29Buy4.153,61414,9987,911Feb 03 08:21 PM
NACHTSHEIM JAMI KDirectorJan 29Buy4.152,41010,0022,410Feb 03 08:18 PM
Witney FrankDirectorJan 29Buy4.1524,09699,99860,305Feb 03 08:17 PM
BJERKHOLT ERICDirectorJan 29Buy4.1520,00083,00024,282Feb 03 08:16 PM
Swisher Daniel N JRDirectorJan 29Buy4.151,0004,15045,910Feb 06 05:32 PM